Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,
Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )
6 Mar 2026

Evaluation and definition of response and progression from trials to clinical practice

Dr Andrew Armstrong - Duke University, Durham, North Carolina
Evaluation and definition of response and progression from trials to clinical practice ( Dr Andrew Armstrong - Duke University, Durham, North Carolina )
6 Mar 2026

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
6 Mar 2026

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
6 Mar 2026

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies ( Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA )
5 Feb 2026

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma

Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA
Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma ( Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA )
5 Feb 2026

Global cancer burden, prevention, and inequalities across regions

Dr Raúl Murillo - San Ignacio University Hospital, Bogotá, Colombia
Global cancer burden, prevention, and inequalities across regions ( Dr Raúl Murillo - San Ignacio University Hospital, Bogotá, Colombia )
30 Jan 2026

Understanding breast cancer care systems with the BCCi

Dr Benjamin Anderson - University of Washington, Seattle, USA
Understanding breast cancer care systems with the BCCi ( Dr Benjamin Anderson - University of Washington, Seattle, USA )
30 Jan 2026

Improving cancer treatment access in conflict-affected African regions

Dr Fatoumata Sidibe - University Hospital of Point-G, Bamako, Mali
Improving cancer treatment access in conflict-affected African regions ( Dr Fatoumata Sidibe - University Hospital of Point-G, Bamako, Mali )
29 Jan 2026